Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study.

Pérez de Isla L, Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, Miramontes JP, Fuentes F, Gómez de Diego JJ, González-Estrada A, Mata N, Saltijeral A, Barreiro M, Tomás M, de Andrés R, Argüeso R, Serrano Gotarredona MP, Navarro Herrero S, Perea Palazón RJ, de Caralt TM, Suárez de Centi LA, Zhilina S, Espejo Pérez S, Padró T, Mata P; SAFEHEART investigators.

J Clin Lipidol. 2018 Jul - Aug;12(4):948-957. doi: 10.1016/j.jacl.2018.04.003. Epub 2018 Apr 17.

PMID:
29753733
2.

Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry.

Saltijeral A, Pérez de Isla L, Alonso R, Muñiz O, Díaz-Díaz JL, Fuentes F, Mata N, de Andrés R, Díaz-Soto G, Pastor J, Pinilla JM, Zambón D, Pinto X, Badimón L, Mata P; SAFEHEART Investigators.

Rev Esp Cardiol (Engl Ed). 2017 Jun;70(6):444-450. doi: 10.1016/j.rec.2016.10.010. Epub 2016 Nov 29. English, Spanish.

PMID:
27913073
3.

Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study).

Pérez de Isla L, Alonso R, Mata N, Saltijeral A, Muñiz O, Rubio-Marin P, Diaz-Diaz JL, Fuentes F, de Andrés R, Zambón D, Galiana J, Piedecausa M, Aguado R, Mosquera D, Vidal JI, Ruiz E, Manjón L, Mauri M, Padró T, Miramontes JP, Mata P; SAFEHEART Investigators.

Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):2004-10. doi: 10.1161/ATVBAHA.116.307514. Epub 2016 Jul 21.

PMID:
27444203
4.

Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.

Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, Fuentes F, Diaz-Diaz JL, de Andrés R, Zambón D, Rubio-Marin P, Barba-Romero MA, Saenz P, Sanchez Muñoz-Torrero JF, Martinez-Faedo C, Miramontes-Gonzalez JP, Badimón L, Mata P; SAFEHEART Investigators.

J Am Coll Cardiol. 2016 Mar 22;67(11):1278-85. doi: 10.1016/j.jacc.2016.01.008.

5.

Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study.

Fuentes F, Alcala-Diaz JF, Watts GF, Alonso R, Muñiz O, Díaz-Díaz JL, Mata N, Sanchez Muñoz-Torrero JF, Brea Á, Galiana J, Figueras R, Aguado R, Piedecausa M, Cepeda JM, Vidal JI, Rodríguez-Cantalejo F, López-Miranda J, Mata P; SAFEHEART Investigators.

Int J Cardiol. 2015 Dec 15;201:79-84. doi: 10.1016/j.ijcard.2015.07.107. Epub 2015 Aug 5.

PMID:
26296047
6.

Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation.

Alonso R, Andres E, Mata N, Fuentes-Jiménez F, Badimón L, López-Miranda J, Padró T, Muñiz O, Díaz-Díaz JL, Mauri M, Ordovás JM, Mata P; SAFEHEART Investigators.

J Am Coll Cardiol. 2014 May 20;63(19):1982-9. doi: 10.1016/j.jacc.2014.01.063. Epub 2014 Mar 13.

Supplemental Content

Loading ...
Support Center